Markets | |
With restaurant dining rooms only just starting to come back in a lot of places—some have been open for most of a month in at least some capacity—one thing was clear: when the going gets tough, America gets take-out. And take-out pizza was a very big deal in the last month, as reported... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Markets | | Shares of the enigmatic athleisure brand Under Armour (NYSE: UAA) (NYSE: UA) have been in a downtrend since peaking in July 2019 at $27.72 on the heels of its last upbeat earnings report. Management ate crow in the following quarters as they missed guidance and continued to lose credibility with shr... Read the Full Story |
|
Markets | | It’s Not Consensus That Matters
Autozone (AZO) made headlines this morning after it reported consensus-beating results for the calendar 1st quarter. While a consensus beat is a great thing, it does not make a stock a buy, especially if the outlook for future growth is in peril. In the case of... Read the Full Story |
|
From Our Partners | | TradeSmith CEO Keith Kaplan warns that AI's rapid rise has a dark side, threatening American jobs and livelihoods. He says now is the time to prepare before August 31st.
TradeSmith has invested $17 million in AI tools and built a platform used by 180,000 traders worldwide. One user, Stephen, credits it with building a $2.95 million retirement portfolio. | | See where Kaplan says to move your money before August 31st |
|
Markets | | Fantasy sports betting platform Draft Kings (NASDAQ: DKNG) shares have accelerated as a pandemic beneficiary play. The absence of live sports events has caused fans to embark upon fantasy sports to meet their fix with the potential to win cash and prizes. Stay-in-shelter isolation mandates generated... Read the Full Story |
|
Markets | |
Technology moves at a mile a minute these days. This is particularly true in the business world, which is rapidly evolving as a result of new and innovative companies that help companies handle their operations in better and more efficient ways. Look no further than some of the fintech companies t... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Markets | | Target Reports Results And Blows Past The Consensus
Target (TGT) reported earnings this morning and led me to a singular conclusion; tech is going to boom this year. I’m sure by now you’re thinking that I’m either crazy, Target is doing something behind the scenes you don’t ... Read the Full Story |
|
Markets | |
Have you been aching for a lunch of soup, salad and breadsticks at your local Olive Garden? If that's the case, then you're in luck; Darden Restaurants (NYSE: DRI) has a plan to open up almost two out of every three of its dining rooms by the end of the month, and it's not just Olive Garden, eithe... Read the Full Story |
|
Markets | | There’s A Lot Of Good News Out There
The stock market is often an irrational beast and never more so, seemingly than when it is discounting a future event. Take, for instance, the recent correction. The correction was sharp and swift, not because the economy was in decline but because of an e... Read the Full Story |
|
Markets | | Fertility benefits management company Progyny, Inc. (NASDAQ: PGNY) fills a void in health insurance coverage that the world’s leading companies embrace to attract and keep top talent. Infertility coverage that is not deemed ‘medically necessary’ is not covered by most health plans... Read the Full Story |
|
Markets | |
It's been amazing to witness the way that technology has changed how businesses operate over the last decade. With new data storage capabilities that can dramatically improve the efficiency of how companies function, most businesses are quickly making the move to the cloud. Major corporations are ... Read the Full Story |
|
The Early Bird Stock Of The Day BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. | | View Today's Stock Pick |
|
